Bacillus Anthracis Infections Market - Forecast(2024 - 2030)

Bacillus Anthracis Infections Market Overview

Bacillus Anthracis Infections Market Size is estimated to reach $1.3 billion by 2027. Furthermore, it is poised to grow at a CAGR of 7.9% over the forecast period of 2022-2027. Bacillus anthracis is bacteria responsible for diseases called ‘anthrax’, and it is able to infect animals and humans. Bacillus anthracis has the ability to form spores that protect them in any harsh and mild conditions for a prolonged period of time. Anthrax shows cutaneous anthrax symptoms, inhalation anthrax symptoms, gastrointestinal anthrax symptoms, and injection anthrax symptoms which include further various symptoms of anthrax. The Symptoms of anthrax depend on the type of infection and take 1 day to more than 2 months to appear. People with severe symptoms of anthrax need hospitalization. Recently on August 24, 2021, The Texas Animal Health Commission (TAHC), received new confirmation of anthrax in white-tailed deer with a total of 9 different locations in Austin. Treatment for anthrax includes several medications with antibiotics, antitoxin, and drugs like ciprofloxacin, levofloxacin, and doxycycline. Infections of the lungs, such as the common cold, influenza, pneumonia, and respiratory failure, are crucial indicators of Bacillus anthracis infection. Anthrax disease is diagnosed by a sample of fluid or by biopsy using a blood test, chest x-ray, computerized tomography (CT) scan, gram test, PCR assay, and other methods.

There is a focus on the development of new medicines and diagnostics methods to diagnose treat and cure an infection of Bacillus anthracis. The increasing threat of exposure to Bacillus anthracis by civilians, military forces, and lab technicians lead to the development of new medication and treatments to treat anthrax disease which helps to drive the growth of the Bacillus Anthracis Infections Market over the forecast period 2022-2027.

Report Coverage

The report: “Bacillus Anthracis Infections Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Bacillus Anthracis Infections Market.

By Anthrax Type: Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax, and Injection Anthrax.
By Treatment: Anti-Biotics, Anti-Toxin, and Others.
By Route of Administration: Oral and Parental.
By End Use: Hospitals & Clinics, Commercial or Private Laboratories, Public Health Laboratories, and Others.
By Geography: North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and the Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

• Geographically, North America held a dominant market share in the year 2021, owing to advanced health infrastructure in countries like the United States and Canada.
• The Bacillus Anthracis Infections Market is predicted to increase owing to the increasing prevalence of anthrax diseases in animals and humans.
• However, the high cost of treatment and false diagnoses may limit market growth over the forecast period 2022-2027.
• A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Bacillus Anthracis Infections Market Report.

Bacillus Anthracis Infections Market Segmentation Analysis- By Anthrax Type

Bacillus Anthracis Infections Market based on anthrax type can be further segmented into Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax, and Injection Anthrax. The cutaneous Anthrax segment held a dominant market share in the year 2021. Cutaneous Anthrax disease is the most common type of anthrax and causes more than 80% of total cases. Also, the trend of consuming raw and less processed meat increases the chances of disease transmission from gastrointestinal routes. Cutaneous anthrax is caused by a cut or wound which has a higher chance of infection during handling an infected animal or contaminated animal product. Such direct contact of infections by anthrax disease creates a need to better treatment and measures to cure such infections, such factors help to drive Bacillus Anthracis Infections Market.

However, Inhalation anthrax is estimated to grow with the fastest CAGR rate of 8.2% over the forecast period. The growth can be due to the easy transmission of anthrax spores through the air medium. People who work at the wool mill, slaughterhouse, and tanneries have high chances of infection by inhalation of anthrax. Australia is the largest producer of wool and produces 345 million kilos of wool every year and the country has high chances of inhalation anthrax infections. Inhalation anthrax can be life-threatening anthrax disease without medication and with proper medicine chances of survival can come close to 55%. Owing to such a high mortality rate, the segment of inhalation anthrax helps to grow Bacillus Anthrax Infections Market over the forecast period 2022-2027.

Bacillus Anthracis Infections Market Segmentation Analysis- By Treatment

Bacillus Anthracis Infections Market based on end-use can be further segmented into Hospitals, Commercial or Private Laboratories, Public Health Laboratories, and Others. The Hospital segment held a dominant market share in the year 2021. This is owing to the use of improved diagnostic technology over time in hospitals. Anthrax is diagnosed by chest X-ray, and a CT scan shows pleural effusion in patients with inhalation anthrax. In many hospitals, there is an advanced radiology lab to perform such tests, and some prefer to tie up with outside clinical laboratories for such tests on a contract basis. In such clinical laboratories, the diagnosis of anthracis is possible owing to an advanced technique like an x-ray or CT scan for anthracis diagnostics which fuels market growth of the segment.

However, Commercial or Private laboratories are estimated to grow with the fastest CAGR rate of 8.8% over the forecast period 2022-2027. Owing to the increasing number of private diagnostic laboratories across the globe and reliable techniques used for diagnostic specific lab tests using fecal specimens. According to National Accreditation Board for Testing and Calibration Laboratories, there is a total of 17025 testing laboratories accredited in accordance with ISO standard 15189:2012 in 2022, and 15189 ISO-certified medical laboratories in India. Such numbers of registered laboratories for diagnosis to grow the Bacillus Anthracis Infections Market over the forecast period.

Bacillus Anthracis Infections Market Segmentation Analysis- By Geography

The Bacillus Anthracis Infections Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 32% in the year 2021. Increase in healthcare infrastructure, high expenditure on health, and continuous developments to minimize infections by high government funding. In 2019, the United States funded WHO and UNICEF $US 105 million and $US 84 million respectively to expand surveillance, maintain the global laboratory network, secure vaccinations, support technical assistance for countries, and mobilize communities. Owing to such a huge amount of investment in the healthcare sector by the government and the presence of global leading market players in the region help drive the Bacillus Anthracis Infections Market.

Furthermore, the Asia-Pacific is estimated to grow with the fastest CAGR over the forecast period 2022-2027, owing to the increasing number of cases reported in past years. In Kazakhstan, 154 strains of Bacillus Anthracis were identified using Multiple Locus VNTR (variable number of tandem repeats) as per the Frontier Journal report published in December 2021. In August 2021, China reported to Beijing Centre for Disease Control and Prevention about an anthrax case in northern Hebei Province's Chengde city. Such frequent outbreak of deadly anthrax disease and large population density in this region in some countries like China, India, and Indonesia creates a risk of high infection rates, and the risk of bioweapons using anthrax pushed governments and organization for research and developments to diagnose, treat and cure infectious diseases, also the presence of key market players and their innovations help to grow market over the forecast period.

Bacillus Anthracis Infections Market Drivers

Increasing Population and Rising Awareness About Anthrax Disease Infection Drives The Market Growth

The world population is increasing day by day owing to low mortality rates and advanced healthcare facilities. In 2022, around 7.9 billion human population is recorded all around the world, and most of the people are non-vegetarians. As consumption of infected raw meat increases, the chances of disease also increase. In 2021, Zimbabwe reported more than 200 anthrax cases as per the WHO report. Another incidence from India reported 1 death and 5 infected in Odisha at Lamataput block. Also, the availability of better medication and vaccinations helps drive market growth.

Growth In Technological Advancements for Anthrax Testing Expand The Global Industry

Diagnosis of anthrax is very difficult without the use of advanced technology, as it shows atypical symptoms. Anthrax infection creates complex syndromes that make it hard to diagnose. To diagnose anthrax, doctors suggest various tests like a biopsy, blood test, chest X-ray, computerized tomography (CT) scan, stool testing, and lumbar puncture to accurately diagnose the type of anthrax infection. Recently in December 2021, a scientist from the U.S Army Medical Research Institute of Infectious Disease (USAMRIID) completed a successful experiment on mice with enzyme treatment. All mice infected with anthrax spores were completely protected after treatment with a pegylated enzyme known as PEG-CapD-CPS334C. In 2019, Food and Drug Administration (FDA) approved Anthim (obiltoxaximab) injection, for intravenous use, Anthrasil (Anthrax Immune Globulin), and BioThrax vaccine to treat and prevent anthrax disease. Also, various key market players invest to develop drugs to treat anthrax, for instance, the Biomedical Advanced Research and Development Authority BARDA upgrades its contract with Emergent Biosolutions to provide an extra dose of valued $258 million company’s upcoming anthrax vaccine ‘Nuthrax’ in July 2020. Such novel drugs in the market help to grow the Bacillus Anthracis Infections Market growth.

Bacillus Anthracis Infections Market Challenges

High Cost of Treatment and False Diagnosis May Hinder Market Growth

Inhalation anthrax and its subsequent systemic infections have a mortality rate of up to 100%. The mortality rate of inhalation anthrax and gastrointestinal anthrax is remained up to 40% to 45% respectively even after modern-day technology and present-day critical care facility as per the Medscape report published in April 2021. Also, infectious diseases are rapidly increasing in the past few years. The Centers for Disease Control and Prevention estimates that 23,000 Americans with these infections die each year. According to a research article published in Health Affairs, infectious diseases cost $20 billion each year. Such high mortality and treatment costs may hamper Bacillus Anthracis Infections Market over the forecast period 2022-2027.

Bacillus Anthracis Infections Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Bacillus Anthracis Infections Market. The top 10- Bacillus Anthracis Infections Market companies are-

1. Altimune Inc
2. Elusys Therapeutics, Inc
3. Emergent Biosolutions, Inc
4. Proton Biopharma
5. Pfizer Inc
6. ContraFect Corporation
7. Evolva SA
8. Aphios Corporation
9. Cellceutix Corporation
10. Microbiotix, Inc

Recent Developments

• In May 2022, Emergent BioSolutions announced a definitive agreement with Chimerix Inc. to acquire Chimerix’s exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the U.S. Food and Drug Administration (FDA) for all age groups for the treatment of smallpox. The acquisition cost $225 million in cash.
• In April 2022, Elusys Therapeutics, a commercial biodefence company and developer of ANTHIM (treatment for inhalation anthrax) was completely acquired by Heat Biologics, a fully integrated biopharmaceutical company with a focus on developing first-class pharmaceuticals. Under this acquisition Heat biologics acquired all outstanding shares of Elusys.
• In March 2021, Altimmune Inc. entered into a collaboration with Lonza to expand the production of AdCOVID -the single-dose intranasal vaccine for COVID-19. AdCOVID activates systemic immunity (neutralizing antibodies and T cell responses) and mucosal immunity in the respiratory tract which has been proved in preclinical studies.
  

Relevant Titles

Mycoplasma Testing Market - Forecast(2022 - 2027)

Report Code: HCR 0429

Respiratory Syncytial Virus Diagnostic Testing Market - Forecast(2022 - 2027)

Report Code: HCR 0826

Ampicillin Market Analysis - Forecast(2022 - 2027)

Report Code: CMR 0246